The Boao Yianke LV009 injection, a cellular therapy product, has completed its first patient dosing.

Recently, Anke Biotechnology's affiliated company Biosun Ji'an announced that its independently developed intracellular cell therapy product LV009 injection has completed the first patient dosing, marking the official entry of Biosun Ji's CAR-T/NK technology into a new era of "in vivo generation" from "ex vivo customization". LV009, through breakthrough lentiviral vector technology, has achieved efficient transfection of resting T cells and NK cells, capable of simultaneously generating CAR-T and CAR-NK cells targeting CD19, promising a disruptive breakthrough in the treatment of B cell malignancies.